Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWB-103 in Split-Thickness Skin Graft Donor Site Wounds
NCT02737748Phase 2Completed
- Sponsor
- Transwell Biotech Co., Ltd.
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Hydrogel Systems, Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of recombinant human acidic fibroblast growth factor in split-thickness skin graft donor site wound, sponsored by Transwell Biotech Co., Ltd.. Started Jul 2017; status: completed.
02
Drugs
recombinant human acidic fibroblast growth factor
03
Conditions
split-thickness skin graft donor site wound
Beyond the preview
Go deeper on NCT02737748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737748.